May 25, 2021
The Ministry of Health, Labor and Welfare (MHLW) on May 24 granted orphan drug designations to three APIs including Alexion Pharmaceuticals’ eculizumab for the treatment of Guillain-Barre syndrome. Eculizumab’s Guillain-Barre syndrome indication has already earned the sakigake fast-track designation, the...read more